Unlock instant, AI-driven research and patent intelligence for your innovation.

Immunotherapy of B cell malignancies and autoimmune disease using unconjugated antibodies and conjugated antibodies, antibody combinations and fusion proteins

一种B细胞、疾病的技术，应用在T细胞相关病或自身免疫病,治疗和诊断哺乳动物B细胞相关病,渐进性非霍奇金氏淋巴瘤的免疫治疗领域，能够解决不可判断放射性免疫治疗预先投药等问题

Inactive Publication Date: 2011-07-27
IMMUNOMEDICS INC
View PDF21 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, it cannot be judged from these studies whether any prior administration is necessary for this type of radioimmunotherapy, especially radioimmunotherapy with CD22 antibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0118] Antibody

[0119] Epratuzumab is a humanized LL2 antibody developed by Immunomedics Inc., Morris Plains, NJ. Human IgG used in humanization process 1 The sequence replaced approximately 95% of the murine Ig sequence. Epratuzumab is internalized upon binding to the B epitope of the CD22 antigen (Stein, R. et al., Cancer Immunol. Imnaunother. 37(5):293-8, 1993), which corresponds to the third Ig domain (Kehrl , J.H.B6 CD22 Workshop Panel Report, in Leubocyte Typing V. White Cell Differentiation Antigens., S.F. Schlossman (ed.). Oxford University Press, p.523-5, 1995). Internalization in vitro was observed after 5 minutes and reexpression of up to 50% of the antigen was reported to occur after 5 hours (Shih, L.B. et al. Int J Cancer 56(4):538-45, 1994).

[0120] The humanized anti-CD20 antibody hA20 has been developed by Immunomedics, Inc., Morris Plains, NJ. This Mab binds CD20 and, in contrast to the chimeric anti-CD20 MAb rituximab, is a CDR-grafted MAb with less mu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention is directed to a method for treating a treating and diagnosing a B cell-related disease, T cell-related disease or an autoimmune disease in a mammal by concurrently or sequentially administering to the mammal a therapeutic composition that comprises a pharmaceutically acceptable vehicle and at least one conjugated antibody, wherein predosing with a non-radiolabeled antibody is not performed.

Description

[0001] This application is a branch of the invention patent application with the application number "200380110054.3" and the invention title "Immunotherapy of B-cell malignancies and autoimmune diseases by using non-conjugated antibodies and conjugated antibodies, antibody combinations and fusion proteins" case application. field of invention [0002] The present invention relates to an immunotherapy method for treating B cell-related malignant tumors, especially progressive non-Hodgkin's lymphoma. Specifically, the present invention relates to methods for treating and diagnosing B-cell-related diseases, T-cell-related diseases or autoimmune diseases in mammals by administering to said mammals a therapeutic composition, wherein no A pre-dosing of non-radiolabeled antibody is performed. Background of the invention [0003] B-cell lymphomas express surface antigens that have proven to be good targets for therapy with monoclonal antibodies (Mabs). Antibodies can be conjugated...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K51/10A61K47/48A61P19/02A61P29/00A61P35/00A61P35/02A61P37/00A61P5/00A61P37/06
CPCA61K51/1093A61K51/109A61K51/1045A61K51/1018A61P1/04A61P1/16A61P11/00A61P13/12A61P17/00A61P17/06A61P19/02A61P21/00A61P21/04A61P25/14A61P25/28A61P29/00A61P35/00A61P35/02A61P37/00A61P37/06A61P5/00A61P5/14A61P7/02A61P7/04A61P7/06A61P9/00A61P3/10A61K39/395A61K39/00C07K16/2812C07K16/2815C07K16/2821C07K16/2827C07K16/2845C07K16/2851C07K16/2878C07K16/2887C07K16/2893C07K16/2896
Inventor D·M·戈登伯格H·汉森
Owner IMMUNOMEDICS INC